ADE LLC’s Revance Therapeutics, Inc. RVNC Stock Holding History

ADE LLC’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-225	Closed	-$6K	–	320
2020 Q4	$6K	Buy	+225	New	+$5.83K	﹤0.01%	288

Other funds holding RVNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ADE LLC's RVNC Position: Q1 2021 in Review

ADE LLC sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2021, closing a stake of 225 shares — an estimated $6K sold.

ADE LLC first reported a position in RVNC in Q4 2020 and held it in 1 quarter. The position peaked at $6K in Q4 2020. 149 funds tracked by Wall St. Rank hold RVNC as of Q1 2021.

ADE LLC reported no remaining Revance Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
ADE LLC sold 225 Revance Therapeutics, Inc. shares in Q1 2021, an estimated $6K.
ADE LLC first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 1 quarter.
ADE LLC's Revance Therapeutics, Inc. position peaked at $6K in Q4 2020.
149 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2021.

Based on ADE LLC's 13F filing for Q1 2021, filed 16 Apr 2021.